In silico prediction and experimental evaluation of LIP3228 of pathogenic Leptospira as a potential subunit vaccine

Yaowarin Nakornpakdee1, Teerasit Techawiwattanaboon2, Saowaros Prasai1

  • 1Department of Pathobiology, Faculty of Science, Mahidol University, Ratchathewi, Bangkok, 10400, Thailand.

Insights

This study explored the LIP3228 protein as a potential leptospirosis vaccine. While it showed immunogenicity and reduced tissue damage in hamsters, it did not improve survival rates, suggesting potential for mitigating disease severity.

Area of Science:

  • Vaccinology
  • Immunology
  • Infectious Diseases

Background:

  • Leptospirosis remains a global health concern, necessitating novel vaccine strategies.
  • Protein subunit vaccines utilizing conserved surface-exposed outer membrane proteins (SE-OMPs) are promising for leptospirosis.
  • The LIP3228 protein is a conserved SE-OMP identified as a potential vaccine candidate.

Purpose of the Study:

  • To assess the in silico immunological properties of the LIP3228 protein.
  • To validate the immunogenicity and protective efficacy of LIP3228 in a hamster model of leptospirosis.

Main Methods:

  • In silico immunoinformatic predictions of B-cell and T-cell epitopes.
  • Immune simulator analysis of interactions with Toll-like receptors (TLR2 and TLR4).
  • Hamster immunization with recombinant LIP3228 and AddaVax adjuvant, followed by challenge with virulent Leptospira.

Main Results:

  • In silico analysis predicted LIP3228 to be immunogenic with strong epitope binding.
  • Immunization induced high, specific IgG responses in hamsters, predominantly IgG2.
  • Vaccinated hamsters exhibited reduced histopathological damage and lesion severity, but no significant survival improvement.

Conclusions:

  • Immunoinformatic prediction effectively indicated immunogenicity but not protective efficacy.
  • LIP3228 shows potential as a vaccine candidate for reducing leptospirosis-associated tissue damage.
  • Further research into LIP3228 and similar subunit antigens is warranted for future vaccine development.